Published August 1, 2026 | Version v1
Journal article Open

OBEZİTEDE İDEAL KİLODAN EN SAĞLIKLI KİLOYA: HEDEF BELİRLEMEDE YENİ PARADİGMA

Authors/Creators

Files

4.1.1.pdf

Files (1.1 MB)

Name Size Download all
md5:df9b1a7363edbc36d0b6c7692861a26f
1.1 MB Preview Download

Additional details

References

  • 1. Cho S, Kwon H. Current guidelines and future directions in comprehensive obesity assessment. Korean J Fam Med. 2026;47(1):4-11.
  • 2. Türkiye Endokrinoloji ve Metabolizma Derneği (TEMD). TEMD Obezite Tanı, Tedavi ve İzlem Kılavuzu. Ankara: TEMD; 2024.
  • Wharton S, Lau DCW, Vallis M, Sharma AM, Biertho L, Campbell-Scherer D, et al. Obesity in adults: a clinical practice guideline. CMAJ. 2020;192(31):E875-E891.
  • Kirk SFL, Ramos Salas X, Russell-Mayhew S. Reducing weight bias in obesity management, practice and policy. Canadian Adult Obesity Clinical Practice Guidelines; 2020.
  • Sweatt K, Garvey WT, Martins C. Strengths and limitations of BMI in the diagnosis of obesity: what is the path forward? Curr Obes Rep. 2024;13(3):584-595.
  • Nadolsky K, Garvey WT, Agarwal M, Bonnecaze A, Burguera B, DeGeeter Chaplin M, et al. American Association of Clinical Endocrinology consensus statement: algorithm for the evaluation and treatment of adults with obesity/adiposity-based chronic disease – 2025 update. Endocr Pract. 2025;31(11):1351-1394.
  • Zahid S, Peng AW, Razavi AC, Yao Z, Blumenthal RS, Blaha MJ. Center stage: putting obesity staging systems into the spotlight. Prev Chronic Dis. 2025;22:250222.
  • VA/DoD (Sigma Health Consulting). VA/DoD clinical practice guideline for the management of overweight and obesity in adults. Washington (DC): Department of Veterans Affairs, Department of Defense.
  • A review of current guidelines for the treatment of obesity. Am J Manag Care. 2022;28(15 Suppl):S288-S296.
  • Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391(10120):541-551.
  • Look AHEAD Research Group, Gregg EW, Jakicic JM, Blackburn G, Bloomquist P, Bray GA, et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2016;4(11):913-921.
  • Ryan DH, Lingvay I, Deanfield J, Kahn SE, Barros E, Burguera B, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024;30(7):2049-2057
  • Prado CM, Batsis JA, Donini LM, Gonzalez MC, Siervo M. Sarcopenic obesity in older adults: a clinical overview. Nat Rev Endocrinol. 2024;20(5):261-277.
  • Türkiye Endokrinoloji ve Metabolizma Derneği (TEMD). Tıbbi Beslenme ve Egzersiz Metabolizması Kılavuzu. Ankara: TEMD; 2023.
  • Chao AM, Paul A, Hodgkins JV, Wadden TA. A guideline-directed approach to obesity treatment. Diabetes Spectr. 2024;37(4):281-295
  • Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.
  • Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.